Sunil S. Badve, MD, FRCPath is vice chair for pathology cancer programs and professor in the Department of Pathology and Laboratory Medicine at Emory University School of Medicine.
Case 2: Recommendations for Approaching Treatment of HR+ Breast Cancer
March 7th 2022A panel of breast cancer experts share recommendations for adjuvant chemotherapy and endocrine therapy for a patient with HR-positive breast cancer and discuss approaches to toxicity management to increase adherence to therapy.
Case 1: Clinical Implications From MonarchE in HR+ Early Breast Cancer
February 28th 2022Heather McArthur, MD; Massimo Cristofanilli, MD, FACP; Sunil Badve, MD, FRCPath; and Joyce O’Shaughnessy, MD, share insight on applying data presented from the monarchE study and the use of adjuvant abemaciclib in clinical practice for high-risk, HR+ early breast cancer.
Case 1: Using Adjuvant Abemaciclib for High-Risk HR+ Early Breast Cancer
February 28th 2022Joyce O’ Shaughnessy, MD; Sunil Badve, MD, FRCPath; and Massimo Cristofanilli, MD, FACP, consider the role of adjuvant abemaciclib plus endocrine therapy for the treatment of patients with high-risk, node-positive, HR+ early breast cancer.
Case 1: MonarchE Study in High-Risk, HR+ Early Breast Cancer
February 28th 2022Heather McArthur, MD; Massimo Cristofanilli, MD, FACP; Sunil Badve, MD, FRCPath; and Joyce O’ Shaughnessy, MD, review the study design and clinical implications from the monarchE study for high-risk, HR+ early breast cancer.